UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Trial of Solanezumab in Preclinical Alzheimer’s Disease

The New England journal of medicine, 2023-09, Vol.389 (12), p.1096-1107

2023

Volltextzugriff (PDF)

Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies

Alzheimer's & dementia, 2023-10, Vol.19 (10), p.4619-4628

2023

Volltextzugriff (PDF)

A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease

PloS one, 2015-03, Vol.10 (3), p.e0119632-e0119632

2015

Volltextzugriff (PDF)

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia

Alzheimer's & dementia : translational research & clinical interventions, 2022, Vol.8 (1), p.e12313-n/a

2022

Volltextzugriff (PDF)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

Alzheimer's & dementia : translational research & clinical interventions, 2015-09, Vol.1 (2), p.111-121

2015

Volltextzugriff (PDF)

Statistical properties of continuous composite scales and implications for drug development

Journal of biopharmaceutical statistics, 2017-11, Vol.27 (6), p.1104-1114

2017

Volltextzugriff (PDF)

Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P262-P263

2015

Volltextzugriff (PDF)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2022, Vol.14 (1), p.e12367-n/a

2022

Volltextzugriff (PDF)

Safety of solanezumab in the expedition-ext study up to 2 years in a mild to moderate Alzheimer’s disease population

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P741-P741

2015

Volltextzugriff (PDF)

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

JAMA neurology, 2020-06, Vol.77 (6), p.735

2020

Volltextzugriff (PDF)

Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database

Current drug safety, 2010-07, Vol.5 (3), p.203

2010

Volltextzugriff (PDF)

Seizure risk in patients with attention‐deficit‐hyperactivity disorder treated with atomoxetine

Developmental medicine and child neurology, 2007-07, Vol.49 (7), p.498-502

2007

Volltextzugriff (PDF)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2016, Vol.2 (1), p.105-112

2016

Volltextzugriff (PDF)

The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database

Current drug safety, 2008-05, Vol.3 (2), p.123

2008

Volltextzugriff (PDF)

P1‐369: AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION

Alzheimer's & dementia, 2019-07, Vol.15, p.P394-P395

2019

Volltextzugriff (PDF)

Implementation of Home Infusions in a Multinational Preclinical Alzheimer’s Disease Study

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Volltextzugriff (PDF)

Neuroimaging Results and A4 in the Context of the LEARN Study

Alzheimer's & dementia, 2023-12, Vol.19 (S24)

2023

Volltextzugriff (PDF)

Longitudinal cerebrospinal fluid phosphorylated tau181 and total tau do not reflect tau PET retention in dominantly inherited Alzheimer disease

Alzheimer's & dementia, 2022-12, Vol.18 (S6), p.n/a

2022

Volltextzugriff (PDF)

IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P1399-P1399

2019

Volltextzugriff (PDF)

P4‐290: IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_27), p.P1399-P1399

2019

Volltextzugriff (PDF)

P1‐369: AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_7)

2019

Volltextzugriff (PDF)

AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P394-P395

2019

Volltextzugriff (PDF)

P4‐172: DELAYED‐START ANALYSES OF SOLANEZUMAB PHASE 3 EXPEDITION STUDIES IN MILD ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_23), p.P852-P852

2014

Volltextzugriff (PDF)

DELAYED-START ANALYSES OF SOLANEZUMAB PHASE 3 EXPEDITION STUDIES IN MILD ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P852-P852

2014

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(43)

Publikationsform

Sprache

Englisch
(47)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Trial of Solanezumab in Preclinical Alzheimer’s Disease

Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies

A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

Statistical properties of continuous composite scales and implications for drug development

Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

Safety of solanezumab in the expedition-ext study up to 2 years in a mild to moderate Alzheimer’s disease population

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

Characteristics and mortality among hospitalized patients treated with intramuscular antipsychotics: analysis of a United States hospital database

Seizure risk in patients with attention‐deficit‐hyperactivity disorder treated with atomoxetine

Function and clinical meaningfulness of treatments for mild Alzheimer's disease

The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database

P1‐369: AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION

Implementation of Home Infusions in a Multinational Preclinical Alzheimer’s Disease Study

Neuroimaging Results and A4 in the Context of the LEARN Study

Longitudinal cerebrospinal fluid phosphorylated tau181 and total tau do not reflect tau PET retention in dominantly inherited Alzheimer disease

IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL

P4‐290: IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL

P1‐369: AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION

AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION

Characterization of amyloid‐related imaging abnormality in the DIAN‐TU‐001 trial

P4‐172: DELAYED‐START ANALYSES OF SOLANEZUMAB PHASE 3 EXPEDITION STUDIES IN MILD ALZHEIMER'S DISEASE

DELAYED-START ANALYSES OF SOLANEZUMAB PHASE 3 EXPEDITION STUDIES IN MILD ALZHEIMER'S DISEASE

Suchergebnisse filtern